Limhamn, Sweden

Nils-Olof Lindberg

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 35(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Nils-Olof Lindberg: Innovator in Cholestyramine Formulations

Introduction

Nils-Olof Lindberg is a prominent inventor based in Limhamn, Sweden. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of cholestyramine delivery systems. With a total of 10 patents to his name, Lindberg's work has had a notable impact on the treatment of bile acid malabsorption.

Latest Patents

Lindberg's latest patents include innovative oral formulations for the targeted delivery of cholestyramine to the colon. One of his inventions involves a formulation comprising a plurality of cholestyramine pellets that are coated with a colon release coating. This formulation is designed to enhance the treatment of bile acid malabsorption. Another patent features a similar oral formulation, but with a diffusion-controlled inner coating and an enteric outer coating, further improving the efficacy of cholestyramine in clinical applications.

Career Highlights

Throughout his career, Nils-Olof Lindberg has worked with notable companies such as Albireo AB and Gedea Biotech AB. His expertise in pharmaceutical formulations has positioned him as a key figure in the development of innovative treatments for gastrointestinal disorders.

Collaborations

Lindberg has collaborated with esteemed colleagues, including Per-Göran Gillberg and Nils Ove Gustafsson. These partnerships have contributed to the advancement of his research and the successful development of his patented formulations.

Conclusion

Nils-Olof Lindberg's contributions to the field of cholestyramine formulations demonstrate his commitment to improving patient care through innovative solutions. His patents reflect a deep understanding of pharmaceutical science and a dedication to addressing medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…